<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895609</url>
  </required_header>
  <id_info>
    <org_study_id>SUNDRO</org_study_id>
    <nct_id>NCT00895609</nct_id>
  </id_info>
  <brief_title>Sugammadex and Neostigmine at Shallow Neuromuscular Blockade</brief_title>
  <acronym>SUNDRO</acronym>
  <official_title>Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.5)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare recovery times after reversal of a residual neuromuscular
      block (TOF-ratio 0.5) with different doses of either neostigmine or sugammadex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Muscle relaxants are integral part of modern anesthesia. They optimize intubating conditions,
      reduce laryngeal trauma and improve operating conditions. Drawback is a possible
      pharmacological (muscle relaxing) effect of these drugs beyond the end of the operation (i.e.
      post-operative residual curarization: PORC). Reportedly about 30% of all patients who
      received muscle relaxants show signs of PORC when arriving in the post-anesthesia care unit.
      PORC comprises the risk of impaired post-operative fine motor and coordinative skills with a
      possible impairment of swallowing pharyngeal secretions with an increased risk of aspiration
      after extubation. Possible deleterious effects of this could be pneumonia, bronchitis,
      myocardial infarction, cardiac insufficiency, stroke or re-operation.

      In order to avoid PORC patients with residual neuromuscular block receive a muscle relaxant
      antagonist from the anesthetist at the end of the operation. However, these drugs
      (neostigmine, pyridostigmine, etc.) from the class of cholinesterase inhibitors have unwanted
      effects such as bradycardia, increased gastro-intestinal motility, post-operative nausea and
      vomiting, salivation etc. To decrease these unwanted side effects cholinesterase inhibitors
      have to be given in combination with parasympatholyics e.g. atropine or glycopyrrolate with
      their own spectrum of unwanted side effects.

      From October 2008 on, Sugammadex, a completely new reversal drug was introduced in to
      clinical practice. Sugammadex, is a modified gamma-cyclodextrine able to specifically bind
      rocuronium (a steroidal muscle relaxant). The complex is eliminated via the kidneys. However,
      all studies so far have focussed on reversal of profound or deep neuromuscular blockade. This
      study is designed to compare recovery times after reversal of a residual neuromuscular block
      (TOF-ratio 0.5) with different doses of either the neostigmine or sugammadex.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to TOF-ratio 0.9 following the investigational drug</measure>
    <time_frame>Regular anesthesia time, approximately 1 hour</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Neuromuscular Block</condition>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex in doses: 0 (placebo), 0.0625, 0.125, 0.25, 0.5 and 1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neostigmine in doses: 0 (placebo), 5, 8, 15, 25, 40 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex, Neostigmine, Saline</intervention_name>
    <description>Single intravenous injection of either:
Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)</description>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_label>Neostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ASA physical status I - III

          -  Patients between 18 and 64 years

          -  Patients scheduled for general anesthesia with intubation using rocuronium

          -  Patients having given informed consent to the study

        Exclusion Criteria:

          -  Anatomic and functional malformations with expected difficult intubation

          -  Known or suspected neuromuscular disease

          -  Significant hepatic or renal dysfunction

          -  Known or suspected history or family history of disposition to malignant hyperthermia

          -  Known or suspected allergy towards sugammadex, anesthetics, muscle relaxants, or other
             drugs used for general anesthesia

          -  Use of drugs that interfere with muscle relaxants

          -  Patients, included in another trial within the last 30 days

          -  Patients, with legal guidant

          -  Patients with contraindication towards the use of Sugammadex, neostigmine or
             glycopyrrolate

          -  Patients, which have already participated in a sugammadex trial

          -  Pregnant women (exclusion of pregnancy: postmenopausal status, negative β- HCG screen,
             status post tubal ligation)

          -  Breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Blobner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>Munic</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008 Nov;109(5):816-24. doi: 10.1097/ALN.0b013e31818a3fee.</citation>
    <PMID>18946293</PMID>
  </reference>
  <reference>
    <citation>Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, Eikermann M, Khuenl-Brady KS. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008 Aug;109(2):188-97. doi: 10.1097/ALN.0b013e31817f5bc7.</citation>
    <PMID>18648227</PMID>
  </reference>
  <reference>
    <citation>Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008 May;100(5):622-30. doi: 10.1093/bja/aen037. Epub 2008 Apr 2.</citation>
    <PMID>18385265</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>March 18, 2013</last_update_submitted>
  <last_update_submitted_qc>March 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <keyword>Residual neuromuscular block</keyword>
  <keyword>post-operative residual curarization</keyword>
  <keyword>PORC</keyword>
  <keyword>sugammadex</keyword>
  <keyword>neostigmine</keyword>
  <keyword>Shallow neuromuscular block (TOF-ratio of 0.5)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

